News Quantified

NUVL – nuvalent, inc. - class a (US:NASDAQ)

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum [Yahoo! Finance]

4/1

06:30 am

nuvl

Medium

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $100.00 price target on the stock.

Nuvalent, Inc. (NASDAQ: NUVL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}